CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Financing Cash Flow
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Financing Cash Flow of $183.06 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-27 was -$164.66M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-28 was $347.72M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-27 was -$51.86M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-27 was -$152.62M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) financing activities for fiscal 2025 was -$536.73M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) financing activities for fiscal 2024 was -$550.93M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) financing activities for fiscal 2023 was -$85.52M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) financing activities for fiscal 2022 was -$42.40M, a 106.30% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-27 | -$164.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $183.06M 10-Q · filed 2026-08-05 | $131.20M derived: sum of 3 quarters · filed 2026-08-05 | -$21.42M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $347.72M 10-Q · filed 2026-05-07 | $295.86M derived: sum of 2 quarters · filed 2026-05-07 | $143.24M derived: sum of 3 quarters · filed 2026-05-07 | -$83.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-27 | -$51.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$204.48M derived: sum of 2 quarters · filed 2026-02-18 | -$431.40M derived: sum of 3 quarters · filed 2026-08-05 | -$536.73M 10-K · filed 2026-02-18 |
| 2025-09-27 | -$152.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$379.54M derived: sum of 2 quarters · filed 2026-08-05 | -$484.86M 10-Q · filed 2025-11-05 | -$560.74M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | -$226.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$332.25M 10-Q · filed 2026-08-05 | -$408.13M derived: sum of 3 quarters · filed 2026-08-05 | -$615.66M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | -$105.33M 10-Q · filed 2026-05-07 | -$181.20M derived: sum of 2 quarters · filed 2026-05-07 | -$388.74M derived: sum of 3 quarters · filed 2026-05-07 | -$674.60M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-28 | -$75.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$283.42M derived: sum of 2 quarters · filed 2026-02-18 | -$569.27M derived: sum of 3 quarters · filed 2026-02-18 | -$550.93M 10-K · filed 2026-02-18 |
| 2024-09-28 | -$207.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$493.39M derived: sum of 2 quarters · filed 2025-11-05 | -$475.05M 10-Q · filed 2025-11-05 | -$351.48M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-29 | -$285.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$267.51M 10-Q · filed 2025-08-06 | -$143.94M derived: sum of 3 quarters · filed 2026-02-18 | -$306.81M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-30 | $18.35M 10-Q · filed 2025-05-07 | $141.91M derived: sum of 2 quarters · filed 2026-02-18 | -$20.95M derived: sum of 3 quarters · filed 2026-02-18 | -$92.42M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-30 | $123.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$39.30M derived: sum of 2 quarters · filed 2026-02-18 | -$110.76M derived: sum of 3 quarters · filed 2026-02-18 | -$85.52M 10-K · filed 2026-02-18 |
| 2023-09-30 | -$162.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$234.33M derived: sum of 2 quarters · filed 2024-11-06 | -$209.09M 10-Q · filed 2024-11-06 | -$458.05M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-07-01 | -$71.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$46.22M 10-Q · filed 2024-08-07 | -$295.18M derived: sum of 3 quarters · filed 2025-02-19 | -$346.77M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-04-01 | $25.24M 10-Q · filed 2024-05-09 | -$223.72M derived: sum of 2 quarters · filed 2025-02-19 | -$275.31M derived: sum of 3 quarters · filed 2025-02-19 | -$3.87M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | -$248.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$300.55M derived: sum of 2 quarters · filed 2025-02-19 | -$29.11M derived: sum of 3 quarters · filed 2025-02-19 | -$42.40M 10-K · filed 2025-02-19 |
| 2022-09-24 | -$51.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $219.84M derived: sum of 2 quarters · filed 2023-11-08 | $206.56M 10-Q · filed 2023-11-08 | -$12.41M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-25 | $271.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $258.15M 10-Q · filed 2023-08-09 | $39.18M derived: sum of 3 quarters · filed 2024-02-14 | $218.08M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-26 | -$13.28M 10-Q · filed 2023-05-11 | -$232.25M derived: sum of 2 quarters · filed 2024-02-14 | -$53.36M derived: sum of 3 quarters · filed 2024-02-14 | $464.60M derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-25 | -$218.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$40.08M derived: sum of 2 quarters · filed 2024-02-14 | $477.88M derived: sum of 3 quarters · filed 2024-02-14 | $672.60M 10-K · filed 2024-02-14 |
| 2021-09-25 | $178.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $696.85M derived: sum of 2 quarters · filed 2022-11-02 | $891.57M 10-Q · filed 2022-11-02 | $832.34M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-26 | $517.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $712.67M 10-Q · filed 2022-08-03 | $653.45M derived: sum of 3 quarters · filed 2023-02-22 | $384.81M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-27 | $194.72M 10-Q · filed 2022-05-04 | $135.49M derived: sum of 2 quarters · filed 2023-02-22 | -$133.15M derived: sum of 3 quarters · filed 2023-02-22 | -$237.24M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-26 | -$59.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$327.87M derived: sum of 2 quarters · filed 2023-02-22 | -$431.96M derived: sum of 3 quarters · filed 2023-02-22 | $47.25M 10-K · filed 2023-02-22 |
| 2020-09-26 | -$268.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$372.74M derived: sum of 2 quarters · filed 2021-11-03 | $106.48M 10-Q · filed 2021-11-03 | $67.43M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-27 | -$104.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $375.12M 10-Q · filed 2021-08-04 | $336.07M derived: sum of 3 quarters · filed 2022-02-16 | $202.63M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-28 | $479.21M 10-Q · filed 2021-05-04 | $440.17M derived: sum of 2 quarters · filed 2022-02-16 | $306.73M derived: sum of 3 quarters · filed 2022-02-16 | $780.23M derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-28 | -$39.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | -$172.49M derived: sum of 2 quarters · filed 2022-02-16 | $301.02M derived: sum of 3 quarters · filed 2022-02-16 | $231.94M 10-K · filed 2022-02-16 |
| 2019-09-28 | -$133.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $340.06M derived: sum of 2 quarters · filed 2020-10-29 | $270.98M 10-Q · filed 2020-10-29 | $271.54M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-06-29 | $473.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $404.42M 10-Q · filed 2020-08-05 | $404.99M derived: sum of 3 quarters · filed 2021-02-17 | $257.91M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-03-30 | -$69.08M 10-Q · filed 2020-05-07 | -$68.52M derived: sum of 2 quarters · filed 2021-02-17 | -$215.60M derived: sum of 3 quarters · filed 2021-02-17 | $503.91M derived: sum of 4 quarters · filed 2021-02-17 |
| 2018-12-29 | $563.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | -$146.52M derived: sum of 2 quarters · filed 2021-02-17 | $573.00M derived: sum of 3 quarters · filed 2021-02-17 | $558.06M 10-K · filed 2021-02-17 |
| 2018-09-29 | -$147.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $572.43M derived: sum of 2 quarters · filed 2019-11-06 | $557.50M 10-Q · filed 2019-11-06 | $504.49M derived: sum of 4 quarters · filed 2020-02-11 |
| 2018-06-30 | $719.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $704.58M 10-Q · filed 2019-07-31 | $651.57M derived: sum of 3 quarters · filed 2020-02-11 | |
| 2018-03-31 | -$14.94M 10-Q · filed 2019-05-07 | -$67.95M derived: sum of 2 quarters · filed 2020-02-11 | ||
| 2017-12-30 | -$53.01M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-11 | -$208.48M 10-K · filed 2020-02-11 | ||
| 2017-09-30 | -$155.47M 10-Q · filed 2018-11-07 | |||
| 2016-12-31 | $380.76M 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |